Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up

Table 3 Clinical outcomes at 1–5 years of follow-up

%	12 months			2 years			3 years			4 years			5 years
%	DM	NDM	P	DM	NDM	P	DM	NDM	P	DM	NDM	P	DM	NDM	P
Cardiac death	1.91	0.92	0.028	3.60	1.42	<.000	4.73	1.76	<.000	5.29	2.34	<.000	5.97	2.66	<.000
Non-cardiac death	0.90	0.41	0.111	2.14	1.10	0.040	3.38	1.7	0.006	4.84	2.11	<.000	5.41	2.57	<.000
Target vessel MI	1.80	1.33	0.324	2.82	1.88	0.130	3.15	2.16	0.121	3.49	2.25	0.060	3.83	2.52	0.057
TLR	3.49	1.65	0.003	4.39	2.71	0.023	4.73	3.12	0.032	5.41	3.63	0.028	5.86	4.08	0.036
TVR	4.62	2.57	0.004	2.14	1.65	0.369	7.21	5.05	0.025	8.33	5.78	0.012	2.82	2.25	0.365
MACE	7.8	4.5	<.000	11.2	6.4	<.000	13.1	7.9	<.000	14.5	9.0	<.000	15.8	10.1	<.000
POCE	11.60	6.79	<.000	15.2	8.44	<.000	18.24	10.6	<.000	21.06	12.25	<.000	22.86	13.72	<.000
TLF	5.97	3.03	<.000	8.67	4.77	<.000	10.25	5.6	<.000	11.15	6.52	<.000	12.39	7.34	<.000
Anginal status
Stable angina	10.54	9.97	0.680	11.07	9.71	0.292	11.4	9.76	0.255	10.41	9.50	0.590	10.57	9.69	0.602
Unstable angina	0.86	1.08	0.684	1.03	0.91	0.827	0.15	0.71	0.127	0.41	0.96	0.373	1.37	0.96	0.454
Silent ischemia	0.74	1.52	0.102	0.90	1.42	0.346	1.06	1.54	0.440	0.41	0.48	1	0.20	0.15	1
No angina	87.87	87.43	0.802	87.00	87.96	0.519	87.39	87.99	0.674	88.78	89.06	0.865	87.87	89.20	0.411

DM diabetes mellitus, NDM patient without DM, IDDM insulin-dependent diabetes mellitus, N number of patients, MI myocardial infarction, TLR target lesion revascularization, TVR target vessel revascularization, MACE major adverse cardiovascular events, POCE patient-oriented composite endpoint, TLF target lesion failure, vs versus

ISSN: 1475-2840